Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): The GOG-0218 validation study

Authors

Benoit You, Universite Claude Bernard (Lyon I)
David Mutch, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

12-1-2022

Volume

40

Issue

34

First Page

3965

Last Page

3974

Document Type

Open Access Publication

DOI

10.1200/JCO.22.01207

Rights and Permissions

You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

You, Benoit; Mutch, David; and et al., "Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): The GOG-0218 validation study." Journal of Clinical Oncology. 40, 34. 3965 - 3974. (2022).
https://digitalcommons.wustl.edu/oa_4/1302

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.